These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4121569)

  • 21. Alterations in brain muscarinic cholinergic receptor binding and choline acetyltransferase activity in Huntington's disease.
    Wastek GJ; Johnson PC; Stern LZ; Yamamura HI
    Proc West Pharmacol Soc; 1976; 19():170-1. PubMed ID: 136659
    [No Abstract]   [Full Text] [Related]  

  • 22. Letter: G.A.B.A. in Huntington's chorea.
    Fisher R; Norris JW; Gilka L
    Lancet; 1974 Jun; 1(7870):1347-8. PubMed ID: 4134677
    [No Abstract]   [Full Text] [Related]  

  • 23. Mammalian tyrosinase. A comparison of tyrosine hydroxylation and melanin formation.
    Hearing VJ; Ekel TM
    Biochem J; 1976 Sep; 157(3):549-57. PubMed ID: 825109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early onset rigid Huntington's disease.
    Bird MT; Paulson GW
    Neurology; 1970 Apr; 20(4):400. PubMed ID: 4254549
    [No Abstract]   [Full Text] [Related]  

  • 25. [Huntington's disease--review on neuroscientific approaches].
    Kanazawa I
    Tanpakushitsu Kakusan Koso; 1984 Dec; 29(14):1815-25. PubMed ID: 6241961
    [No Abstract]   [Full Text] [Related]  

  • 26. The rigid form of Huntington's chorea.
    Bird MT; Paulson GW
    Neurology; 1971 Mar; 21(3):271-6. PubMed ID: 4327152
    [No Abstract]   [Full Text] [Related]  

  • 27. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 28. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What's wrong with epigenetics in Huntington's disease?
    Valor LM; Guiretti D
    Neuropharmacology; 2014 May; 80():103-14. PubMed ID: 24184315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hope for Huntington's from an old antibiotic.
    Ashraf H
    Drug Discov Today; 2005 Dec; 10(23-24):1582-3. PubMed ID: 16376812
    [No Abstract]   [Full Text] [Related]  

  • 31. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain cholesterol therapy for Huntington's disease - Does it make sense?
    Cattaneo E; Barker RA
    Clin Transl Med; 2024 Jul; 14(7):e1746. PubMed ID: 38924677
    [No Abstract]   [Full Text] [Related]  

  • 33. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.
    Mendell JR; Engel WK; Chase TN
    Lancet; 1970 Mar; 1(7647):593-4. PubMed ID: 4190545
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 36. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 37. Parkinsonism and Huntington's chorea.
    Yuill GM
    Lancet; 1971 Jan; 1(7688):44. PubMed ID: 4099351
    [No Abstract]   [Full Text] [Related]  

  • 38. Dopa oxidation and tyrosine oxygenation by human melanoma tyrosinase.
    Jergil B; Lindbladh C; Rorsman H; Rosengren E
    Acta Derm Venereol; 1983; 63(6):468-75. PubMed ID: 6198834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biochemical aspects of Huntington's disease].
    Bonilla E
    Acta Cient Venez; 1977; 28(6):391-7. PubMed ID: 24971
    [No Abstract]   [Full Text] [Related]  

  • 40. [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].
    Kuzuya F; Wakita T; Kawahara H
    Nihon Naika Gakkai Zasshi; 1972 Sep; 61(9):1131-5. PubMed ID: 4674039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.